Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility

被引:98
作者
Dobrinas, M. [1 ]
Cornuz, J. [2 ]
Oneda, B. [1 ,3 ]
Serra, M. Kohler [2 ]
Puhl, M. [2 ]
Eap, C. B. [1 ,4 ]
机构
[1] Univ Lausanne, Hosp Cery, Unit Pharmacogenet & Clin Psychopharmacol, Ctr Psychiat Neurosci,Dept Psychiat,CHUV, Prilly, Switzerland
[2] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[3] Univ Zurich, Inst Med Genet, CH-8603 Schwerzenbach, Switzerland
[4] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland
关键词
CYTOCHROME-P450; 1A2; ACTIVITY; DRUG-INTERACTIONS; 5'-FLANKING REGION; CLOZAPINE; CAFFEINE; POPULATION; TIME; PHARMACOKINETICS; VARIABILITY; OLANZAPINE;
D O I
10.1038/clpt.2011.70
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Cytochrome P4501A2 (CYP1A2) is involved in the metabolism of several drugs and is induced by smoking. We aimed to determine the interindividual change in CYP1A2 activity after smoking cessation and to relate it to CYP1A2 genetic polymorphisms. CYP1A2 activity was determined from the paraxanthine: caffeine ratio in 194 smokers and in 118 of them who had abstained from smoking during a 4-week period. The participants were genotyped for CYP1A2*1F, *1D, and *1C polymorphisms. Smokers had 1.55-fold higher CYP1A2 activity than nonsmokers (P < 0.0001). The individual change in CYP1A2 activity after smoking cessation ranged from 1.0-fold (no change) to a 7.3-fold decrease in activity. In five participants with low initial CYP1A2 activity, an increase was observed after smoking cessation. Before smoking cessation, the following factors were found to influence CYP1A2 activity: CYP1A2*1F (P = 0.005), CYP1A2*1D (P = 0.014), the number of cigarettes/day (P = 0.012), the use of contraceptives (P < 0.001), and -163A/-2467T/-3860G haplotype (P = 0.002). After quitting smoking, only CYP1A2*1F (P = 0.017) and the use of contraceptives (P = 0.05) had an influence. No influence of CYP1A2 polymorphisms on the inducibility of CYP1A2 was observed.
引用
收藏
页码:117 / 125
页数:9
相关论文
共 39 条
[1]
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients [J].
Bondolfi, G ;
Morel, F ;
Crettol, SV ;
Rachid, F ;
Baumann, P ;
Eap, CB .
THERAPEUTIC DRUG MONITORING, 2005, 27 (04) :539-543
[2]
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine [J].
Carrillo, JA ;
Herráiz, AG ;
Ramos, SI ;
Gervasini, G ;
Vizcaíno, S ;
Benítez, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) :119-127
[3]
Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population [J].
Chida, M ;
Yokoi, T ;
Fukui, T ;
Kinoshita, M ;
Yokota, J ;
Kamataki, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09) :899-902
[4]
Dobrinas M, 2009, Rev Med Suisse, V5, P1463
[5]
Nonresponse to clozapine and ultrarapid CYP1A2 activity - Clinical data and analysis of CYP1A2 gene [J].
Eap, CB ;
Bender, S ;
Sirot, EJ ;
Cucchia, G ;
Jonzier-Perey, M ;
Baumann, P ;
Allorge, D ;
Broly, F .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (02) :214-219
[6]
Assessment of CYP1A2 activity in clinical practice: Why, how, and when? [J].
Faber, MS ;
Jetter, A ;
Fuhr, U .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 97 (03) :125-134
[7]
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking [J].
Faber, MS ;
Fuhr, U .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) :178-184
[8]
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans [J].
Ghotbi, Roza ;
Christensen, Magnus ;
Roh, Hyung-Keun ;
Ingelman-Sundberg, Magnus ;
Aklillu, Eleni ;
Bertilsson, Leif .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (06) :537-546
[9]
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms [J].
Gunes, Arzu ;
Dahl, Maija-Liisa .
PHARMACOGENOMICS, 2008, 9 (05) :625-637
[10]
Gunes A, 2009, PHARMACOGENOMICS, V10, P769, DOI [10.2217/pgs.09.22, 10.2217/PGS.09.22]